Franck Emmanuel Nicolini (Franck E Nicolini)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 8

Top Topics

Ejection Fraction

Newly Diagnosed

Tyrosine Kinase

Chronic Myeloid Leukemia

Top Venues

British journal of haematology

American journal of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Vincent Alcazer, Stéphane Morisset, Delphine Rea, Laurence Legros, Stephanie Dulucq, Sandrine Hayette, Jean-Michel Cayuela, Françoise Huguet, François-Xavier Mahon, Gabriel Etienne, Franck Emmanuel Nicolini
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients. British journal of haematology 204 (4) (2024)
Vincent Alcazer, Stéphane Morisset, Delphine Rea, Laurence Legros, Stephanie Dulucq, Sandrine Hayette, Jean-Michel Cayuela, Françoise Huguet, François-Xavier Mahon, Gabriel Etienne, Franck Emmanuel Nicolini
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients. British journal of haematology (2024)
Fady Gh Haddad, Koiji Sasaki, Lewis Fady Nasr, Nicholas James Short, Tapan Mahendra Kadia, Sara Dellasala, Jorge Cortes, Franck Emmanuel Nicolini, Ghayas C Issa, Elias J Jabbour, Hagop M Kantarjian
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase. Cancer 130 (19) (2024)
Fady Gh Haddad, Koiji Sasaki, Lewis Fady Nasr, Nicholas James Short, Tapan Mahendra Kadia, Sara Dellasala, Jorge Cortes, Franck Emmanuel Nicolini, Ghayas C Issa, Elias J Jabbour, Hagop M Kantarjian
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase. Cancer (2024)
Vincent Alcazer, Stéphane Morisset, Delphine Rea, Laurence Legros, Stephanie Dulucq, Sandrine Hayette, Jean-Michel Cayuela, Françoise Huguet, François-Xavier Mahon, Gabriel Etienne, Franck Emmanuel Nicolini
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients. British journal of haematology 204 (4) (2024)
Stephanie Dulucq, Françoise Rigal-Huguet, Franck Emmanuel Nicolini, Pascale Cony-Makhoul, Martine Escoffre-Barbe, Martine Gardembas, Laurence Legros, Philippe Rousselot, Jixing Liu, Delphine Rea, Véronique De Mas, Sandrine Hayette, Sophie Raynaud, Caroline Lacoste-Roussillon, Fanny Robbesyn, Emilie Klein, Stéphane Morisset, François-Xavier Mahon, Gabriel Etienne
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study. British journal of haematology (2023)
Lydia Roy, Jean-Claude Chomel, Joëlle Guilhot, Agnès Guerci-Bresler, Martine Escoffre-Barbe, Stéphane Giraudier, Aude Charbonnier, Viviane Dubruille, Françoise Huguet, Hyacinthe Johnson-Ansah, Pascal Lenain, Shanti Ame, Gabriel Etienne, Franck Emmanuel Nicolini, Delphine Rea, Pascale Cony-Makhoul, Stéphane Courby, Jean-Christophe Ianotto, Laurence Legros, Antoine Machet, Valérie Coiteux, Eric Hermet, Emilie Cayssials, Stéphane Bouchet, Francois-Xavier Mahon, Philippe Rousselot, François Guilhot, null null
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study). British journal of haematology (2022)
Carlo B Gambacorti-Passerini, Franck Emmanuel Nicolini, Richard A Larson, Andrea Aroldi, Diletta Fontana, Rocco Piazza, Philipp le Coutre, Laura Antolini, Sarit Assouline
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia. American journal of hematology 97 (8) (2022)